Cuneo A, Michaux J L, Ferrant A, Van Hove L, Bosly A, Stul M, Dal Cin P, Vandenberghe E, Cassiman J J, Negrini M
Institute of Hematology, University of Ferrara, Italy.
Blood. 1992 Feb 1;79(3):720-7.
Cytogenetic, biomolecular, and clinicopathologic features were retrospectively studied in 34 adult patients with acute myelogenous leukemia expressing one or more of the following lymphoid-associated markers (LMs): CD7, CD2, CD10, CD19, CD22, TdT. Six patients showed 11q23 rearrangements (group I); three patients had the classic Ph chromosome (group II); 15 patients had aberrations of the myeloid type (group III), including four patients with structural aberrations of 13q or trisomy 13, three patients with 7q and 1q anomalies, and two patients with trisomy 11q. Ten patients had a normal karyotype (group IV). Anomalies exclusively associated with lymphoid malignancies were not seen. Ig H and/or T-cell receptor genes were found to be rearranged in 50% and 66% of patients in cytogenetic groups I and II, respectively, versus 8% in group III and 12% in group IV. Likewise, more than one LM was more frequently detected in groups I and II. In group III, two of four patients with aberrations of chromosome 13 expressed two or more lymphoid features. Clinically, patients belonging to cytogenetic groups I and II were generally young, presented with a high white blood cell (WBC) count, and had a low complete remission rate. Survival in Ph chromosome-positive cases was uniformly short. We conclude that although there is no cytogenetic anomaly specifically associated with acute myelogenous leukemia expressing LM, a Morphologic, Immunologic, and Cytogenetic classification may constitute a working basis for further studies aimed at a better definition of clinicopathologic features and optimal treatment strategies for these leukemias.
对34例表达一种或多种下列淋巴样相关标志物(LM)的成年急性髓性白血病患者的细胞遗传学、生物分子和临床病理特征进行了回顾性研究:CD7、CD2、CD10、CD19、CD22、末端脱氧核苷酸转移酶(TdT)。6例患者有11q23重排(I组);3例患者有典型的费城染色体(II组);15例患者有髓系类型的畸变(III组),包括4例有13q结构畸变或13三体的患者、3例有7q和1q异常的患者以及2例有11q三体的患者。10例患者核型正常(IV组)。未发现仅与淋巴样恶性肿瘤相关的异常。在细胞遗传学I组和II组中,分别有50%和66%的患者发现免疫球蛋白重链(Ig H)和/或T细胞受体基因重排,而III组为8%,IV组为12%。同样,I组和II组更频繁地检测到一种以上的LM。在III组中,4例有13号染色体畸变的患者中有2例表现出两种或更多的淋巴样特征。临床上,细胞遗传学I组和II组的患者一般较年轻,白细胞(WBC)计数高,完全缓解率低。费城染色体阳性病例的生存期均较短。我们得出结论,尽管没有与表达LM的急性髓性白血病特异性相关的细胞遗传学异常,但形态学、免疫学和细胞遗传学分类可能构成进一步研究的工作基础,旨在更好地定义这些白血病的临床病理特征和最佳治疗策略。